Table 1.

ADC drugs approved by FDA (up to December 2020)

	ADC name	Brand name	Tumor target Antibody	Linker	Payload DAR	Indication	Pharmaceutical companies	Launch date
1	Mylotarg	Gemtuzumab ozogamicin (GO)	CD33 Humanized IgG4	Cleavable hydrazone linker	Calicheamicin 3–5	CD33 positive acute myeloid leukemia	Pfizer	5/20009/2017*
2	Adcetris	Brentuximab vedotin (SGN-35)	CD30 Chimeric IgG1	Cleavable maleimidocaproyl valine-citrulline linker	MMAE 4	Hodgkin’s lymphoma	Seattle Genetics/Takeda	8/2011
3	Kadcyla	Trastuzumab emtansine (T-DM1)	HER2 Humanized IgG1	Non-cleavable thioether linker	DM1 3–4	HER2 positive breast cancer	Roche	2/2013
4	Besponsa	Inotuzumab ozogamicin	CD22 Humanized IgG4	Cleavable hydrazone linker	Calicheamicin 6	B-cell acute lymphoblastic leukemia	Pfizer	8/2017
5	Lumoxiti	Moxetumomab pasudotox	CD22 Recombinant murine immunoglobulin variable domain	Fusion protein (antibody and payload)	Pseudomonas exotoxin	Hairy cell leukemia	AstraZeneca	9/2018
6	Polivy	Polatuzumab vedotin	CD79b Fully humanized IgG1κ	Cleavable maleimidocaproyl valine-citrulline linker	MMAE 3–4	Diffuse large B-cell lymphoma	Roche	6/2019
7	Padcev	Enfortumab vedotin	Nectin-4 Fully humanized IgG1κ	Cleavable maleimidocaproyl valine-citrulline linker	MMAE 3–4	Urothelial carcinoma	Seattle Genetics/Astellas	12/2019
8	Enhertu	Fam-trastuzumab deruxtecan (DS-8201)	HER2 Fully humanized IgG1κ	Cleavable maleimide tetrapeptide linker	DXd 8	HER2 positive breast cancer	AstraZeneca/Daiichi Sankyo	12/2019
9	Trodelvy	Sacituzumab govitecan	Trop-2 Humanized IgG1κ	Cleavable carbonate linker	SN-38 7–8	Triple-negative breast cancer	Immunomedics	4/2020
10	Blenrep	Belantamab mafodotin	BCMA Humanized IgG1κ	Non-cleavable maleimidocaproyl linker	MMAF 4	Relapsed and refractory multiple myeloma	GlaxoSmithKline	8/2020

^*Mylotarg was first approved in 2000, withdrawn in 2010 and relaunched in 2017.